Trial Title:
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
NCT ID:
NCT05941338
Condition:
Head and Neck Squamous Cell Carcinoma
Oral Cancer
Conditions: Official terms:
Carcinoma
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Mouth Neoplasms
Paclitaxel
Carboplatin
Albumin-Bound Paclitaxel
Conditions: Keywords:
head and neck squamous cell carcinoma
oral cancer
pd-1
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
Description:
Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV),
dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV),
dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab ,
Carboplatin, albumin-bound paclitaxel
Arm group label:
Arm 1
Summary:
In this study, 100 patients with resectable head and neck squamous cell carcinoma (oral
squamous cell carcinoma and oropharyngeal squamous cell carcinoma) were enrolled, who
were combined with tirelizumab, carboplatin and albumin-binding paclitaxel before and
after surgery. Tumor tissues and paracancer tissues of patients were collected to observe
the imaging and pathological changes before and after treatment. At the same time,
clinical information of patients, such as pathological grade, stage, treatment,
prognosis, serology, imaging, etc. were collected to evaluate the safety and feasibility
of tirelizumab combined with carboplatin and albumin-binding paclitaxel for neoadjuvant
therapy of resectable oral and oropharyngeal squamous cell carcinoma. This is a
prospective, one-arm, phase II clinical study.
Purpose Main purpose The efficacy of Tirelizumab combined with carboplatin and
albumin-paclitaxel in neoadjuvant therapy for resectable head and neck squamous cell
carcinoma was evaluated by calculating the major pathological response (MPR) rates in the
experimental group.
The severity of adverse events associated with neoadjuvant therapy will be graded
according to NCI CTCAE (version 5.0) during the course of this study and during
follow-up, the incidence of adverse events in the experimental and control groups will be
compared, and the safety of neoadjuvant therapy with Tirelizumab combined with
carboplatin and albumin-paclitaxel in resectable head and neck squamous cell carcinoma
will be evaluated.
Secondary Purpose
1. One-year event survival rate and event-free survival (EFS) of enrolled patients were
evaluated (five years);
2. Pathological complete response rate (pCR) of enrolled patients was evaluated (5
years);
3. pTR of enrolled patients was evaluated;
4. Overall survival (OS) of enrolled patients was evaluated (5 years);
5. Radiological response of enrolled patients was assessed;
6. The rate of operation delay of enrolled patients was evaluated;
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- 18 years of age ≤65 years of age;
- Cytological or histological diagnosis of surgically resectable squamous cell
carcinoma of the head and neck with the following stages:
T3-4a, N0-2, M0;
- According to the solid tumor efficacy evaluation criteria (RECIST version 1.1),
there was at least one radiologically measurable lesion; First-line patients: have
not previously received any systemic antitumor therapy for advanced/metastatic
disease. Patients who had previously received platinum-containing
adjuvant/neoadjuvant chemotherapy, or had received radical chemoradiotherapy for
advanced disease, if the interval between disease progression or recurrence and the
end of the last chemotherapy drug treatment was at least 6 months, were allowed to
be enrolled in this study.
- ECOG score 0-1;
- Expected survival time > 3 months;
- Adequate organ function, subject shall meet the following laboratory indicators:
1. The absolute value of neutrophil granulocyte (ANC) ≥1.5x109/L in the last 14
days without the use of granulocyte colony stimulating factor;
2. Platelets ≥100×109/L without blood transfusion in the past 14 days;
3. Hemoglobin > without blood transfusion or use of erythropoietin within the
last 14 days; 9g/dL;
4. Total bilirubin ≤1.5× upper limit of normal value (ULN);
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN
(ALT or AST ≤5×ULN in patients with liver metastasis);
6. Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by
Cockcroft-Gault formula) ≥60 ml/min;
7. Good coagulation function, defined as International Standardized ratio (INR) or
prothrombin time (PT) ≤1.5 times ULN;
8. Normal thyroid function, defined as thyroid stimulating hormone (TSH) within
the normal range. Subjects whose baseline TSH is outside the normal range can
be enrolled if total T3 (or FT3) and FT4 are within the normal range;
9. The myocardial enzyme profile was within the normal range (if the researchers
comprehensively judged that the simple laboratory abnormality was not
clinically significant, it was also allowed to be included);
10. For female subjects of childbearing age, a urine or serum pregnancy test should
be tested negative within 3 days prior to receiving the first study drug
administration (day 1 of Cycle 1). If the urine pregnancy test results cannot
be confirmed negative, a blood pregnancy test is requested. Women of
non-reproductive age were defined as at least one year after menopause or
having undergone surgical sterilization or hysterectomy;
11. If there is a risk of conception, all subjects (male or female) shall use
contraception with an annual failure rate of less than 1% for the entire
duration of treatment up to 120 days after the last study drug administration
(or 180 days after the last chemotherapeutic drug administration).
Exclusion Criteria:
- Malignant diseases other than head and neck squamous cell carcinoma diagnosed within
5 years prior to initial administration (excluding basal cell carcinoma of the skin
after radical treatment, squamous epithelial carcinoma of the skin, and/or carcinoma
in situ after radical excision);
- Currently participating in an interventional clinical study, or receiving other
investigational drugs or using investigational devices within 4 weeks prior to
initial dosing;
- Previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that
target another stimulus or synergistic inhibition of T cell receptors (e.g., CTLA-4,
OX-40, CD137);
- Systemic treatment with Chinese patent drugs or immunomodulatory drugs (including
thymosin, interferon and interleukin, except for local use to control pleural
effusion) with indications of anti-head and neck squamous cell carcinoma within 2
weeks before the first administration;
- An active autoimmune immune disease requiring systemic treatment (e.g. with
disease-modifying drugs, glucocorticoids, or immunosuppressants) has occurred within
2 years prior to initial administration. Alternative therapies (such as thyroxine,
insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency) are
not considered systemic therapy;
- Was receiving systemic glucocorticoid therapy (excluding nasal, inhalation, or other
routes of topical glucocorticoids) or any other form of immunosuppressive therapy
within 7 days prior to initial administration; Note: Physiological doses of
glucocorticoids (≤10 mg/ day of prednisone or equivalent) are permitted;
- Clinically uncontrollable pleural effusion/abdominal effusion (patients with no need
to drain effusion or no significant increase of effusion after 3 days of stopping
drainage could be included in the group);
- Known allogeneic organ transplantation (except corneal transplantation) or
allogeneic hematopoietic stem cell transplantation;
- Those who are known to be allergic to the active ingredients or excipients of the
drug in this study, Pabolizumab, carboplatin and albumin-binding paclitaxel;
- Has not fully recovered from toxicity and/or complications caused by any
intervention before starting treatment (i.e., ≤ grade 1 or baseline, excluding
weakness or hair loss);
- Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1/2 antibody
positive);
- Untreated active hepatitis B (defined as HBsAg positive coupled with a detected
HBV-DNA copy number greater than the upper limit of normal in the laboratory of the
study center);
Note: Hepatitis B subjects who meet the following criteria can also be enrolled:
1) HBV viral load < before initial administration; At 1000 copies /ml (200 IU/ml),
subjects should receive anti-HBV therapy to avoid viral reactivation throughout the
study treatment period 2) For subjects with anti-HBC (+), HBsAg (-), anti-HBS (-),
and HBV viral load (-), prophylactic anti-HBV therapy is not required, but close
monitoring of viral reactivation is required
- Active HCV infected subjects (HCV antibody positive and HCV-RNA level above the
lower limit of detection);
- Received live vaccine within 30 days prior to initial administration (cycle 1, day
1); Note: Inactivated injectable virus vaccine against seasonal influenza is
permitted for 30 days prior to initial administration; But live attenuated influenza
vaccines administered intranasally are not allowed.
- Pregnant or lactating women;
- There is any serious or uncontrolled systemic disease, such as:
1. The resting electrocardiogram (ECG) presents significant and severely
uncontrollable abnormalities in rhythm, conduction or morphology, such as
complete left bundle branch block, Ⅱ degree or above heart block, ventricular
arrhythmia or atrial fibrillation;
2. Unstable angina pectoris, congestive heart failure, and NYHA grade ≥ 2 chronic
heart failure;
3. Any arterial thrombosis, embolism or ischemia, such as myocardial infarction,
unstable angina pectoris, cerebrovascular accident or transient ischemic
attack, occurred within 6 months before treatment;
4. Poor blood pressure control (systolic > 140 mmHg, diastolic > 90 mmHg);
5. A history of non-infectious pneumonia requiring glucocorticoid therapy or
clinically active interstitial lung disease within 1 year prior to initial
administration;
6. Active pulmonary tuberculosis;
7. There is an active or uncontrolled infection that requires systemic treatment;
8. Clinically active diverticulitis, abdominal abscess, gastrointestinal
obstruction;
9. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic
active hepatitis;
10. Poor diabetes control (fasting blood glucose (FBG) > 10mmol/L);
11. Urine routine indicated urine protein ≥++, and confirmed 24 hours urine protein
quantity > 1.0 g;
12. Patients with mental disorders and unable to cooperate with treatment; 17.
Medical history or evidence of disease that may interfere with test results,
prevent participants from participating fully in the study, abnormal values of
treatment or laboratory tests, or other conditions that the investigator
considers unsuitable for enrollment. The Investigator considers other potential
risks unsuitable for participation in the study.
Gender:
All
Minimum age:
18 Years
Maximum age:
65 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Sun yat-sun memorial hospital
Address:
City:
Guangzhou
Zip:
510000
Country:
China
Status:
Recruiting
Contact:
Last name:
Haotian Cao
Phone:
008618583879908
Email:
caobleat@hotmail.com
Investigator:
Last name:
Jinsong Li, MD
Email:
Principal Investigator
Start date:
March 1, 2023
Completion date:
February 28, 2030
Lead sponsor:
Agency:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Agency class:
Other
Source:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05941338
